Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study
Kaydedildi:
| Yayımlandı: | American Journal of Public Health vol. 104, no. 6 (Jun 2014), p. E75-E82 |
|---|---|
| Yazar: | |
| Diğer Yazarlar: | , |
| Baskı/Yayın Bilgisi: |
American Public Health Association
|
| Konular: | |
| Online Erişim: | Citation/Abstract Full Text Full Text - PDF |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 1538587464 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 0090-0036 | ||
| 022 | |a 0002-9572 | ||
| 022 | |a 0271-4353 | ||
| 022 | |a 0273-1975 | ||
| 035 | |a 1538587464 | ||
| 045 | 2 | |b d20140601 |b d20140630 | |
| 084 | |a 24825236 | ||
| 084 | |a 8 |2 nlm | ||
| 100 | 1 | |a Frimpong, Jemima A | |
| 245 | 1 | |a Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study | |
| 260 | |b American Public Health Association |c Jun 2014 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs. | |
| 650 | 2 | 2 | |a Financing, Government |x statistics & numerical data |
| 650 | 2 | 2 | |a Health Care Surveys |
| 650 | 2 | 2 | |a Health Services Accessibility |x organization & administration |
| 650 | 2 | 2 | |a Health Services Accessibility |x statistics & numerical data |
| 650 | 1 | 2 | |a Hepatitis C |x diagnosis |
| 650 | 2 | 2 | |a Humans |
| 650 | 2 | 2 | |a Opiate Substitution Treatment |x statistics & numerical data |
| 650 | 1 | 2 | |a Opioid-Related Disorders |x complications |
| 650 | 2 | 2 | |a Substance Abuse Treatment Centers |x organization & administration |
| 650 | 1 | 2 | |a Substance Abuse Treatment Centers |x statistics & numerical data |
| 650 | 2 | 2 | |a United States |
| 651 | 4 | |a United States--US | |
| 653 | |a Substance abuse treatment | ||
| 653 | |a Methadone | ||
| 653 | |a Drug abuse | ||
| 653 | |a Hepatitis | ||
| 653 | |a Medical tests | ||
| 653 | |a Health care industry | ||
| 653 | |a Infections | ||
| 653 | |a Validity | ||
| 653 | |a Trends | ||
| 653 | |a Drug use | ||
| 653 | |a Response rates | ||
| 653 | |a Disease prevention | ||
| 653 | |a Mental health | ||
| 653 | |a Health services | ||
| 653 | |a Onsite | ||
| 653 | |a Narcotics | ||
| 653 | |a Mental health care | ||
| 653 | |a Public health | ||
| 653 | |a Opioids | ||
| 653 | |a Treatment programs | ||
| 653 | |a Medical treatment | ||
| 653 | |a Referrals | ||
| 653 | |a Diagnostic tests | ||
| 653 | |a Availability | ||
| 653 | |a Substance abuse | ||
| 653 | |a Prevention programs | ||
| 653 | |a Buprenorphine | ||
| 653 | |a Blood diseases | ||
| 653 | |a Social | ||
| 700 | 1 | |a D'Aunno, Thomas | |
| 700 | 1 | |a Jiang, Lan | |
| 773 | 0 | |t American Journal of Public Health |g vol. 104, no. 6 (Jun 2014), p. E75-E82 | |
| 786 | 0 | |d ProQuest |t ABI/INFORM Global | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/1538587464/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/1538587464/fulltext/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/1538587464/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |